(Q35610798)

9 August 2017

1 reference

title

Treatment of antiretroviral-drug-resistant HIV-1 infection (English)

1 reference

9 August 2017

main subject

anti-retroviral agent

0 references

1

Steven G Deeks

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

362

1 reference

9 August 2017

issue

9400

1 reference

9 August 2017

page(s)

2002-2011

1 reference

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

In vivo antagonism with zidovudine plus stavudine combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Antiretroviral-drug resistance among patients recently infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Time trends in primary HIV-1 drug resistance among recently infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Viral breakthrough after suppression with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Antiretroviral resistance during successful therapy of HIV type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Prevalence and predictive value of intermittent viremia with combination hiv therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Prevalence and clinical correlates of HIV viremia (`blips') in patients with previous suppression below the limits of quantification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915022-2

7 January 2021

10.1016/S0140-6736(03)15022-2

Identifiers

DOI

1 reference

9 August 2017

1 reference